Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 80

1.

Recurrent somatic mutations in POLR2A define a distinct subset of meningiomas.

Clark VE, Harmancı AS, Bai H, Youngblood MW, Lee TI, Baranoski JF, Ercan-Sencicek AG, Abraham BJ, Weintraub AS, Hnisz D, Simon M, Krischek B, Erson-Omay EZ, Henegariu O, Carrión-Grant G, Mishra-Gorur K, Durán D, Goldmann JE, Schramm J, Goldbrunner R, Piepmeier JM, Vortmeyer AO, Günel JM, Bilgüvar K, Yasuno K, Young RA, Günel M.

Nat Genet. 2016 Oct;48(10):1253-9. doi: 10.1038/ng.3651. Epub 2016 Aug 22.

2.

Increased Nanoparticle Delivery to Brain Tumors by Autocatalytic Priming for Improved Treatment and Imaging.

Han L, Kong DK, Zheng MQ, Murikinati S, Ma C, Yuan P, Li L, Tian D, Cai Q, Ye C, Holden D, Park JH, Gao X, Thomas JL, Grutzendler J, Carson RE, Huang Y, Piepmeier JM, Zhou J.

ACS Nano. 2016 Apr 26;10(4):4209-18. doi: 10.1021/acsnano.5b07573. Epub 2016 Mar 16.

3.

Imaging the delivery of brain-penetrating PLGA nanoparticles in the brain using magnetic resonance.

Strohbehn G, Coman D, Han L, Ragheb RR, Fahmy TM, Huttner AJ, Hyder F, Piepmeier JM, Saltzman WM, Zhou J.

J Neurooncol. 2015 Feb;121(3):441-9. doi: 10.1007/s11060-014-1658-0. Epub 2014 Nov 18.

4.

Highly penetrative, drug-loaded nanocarriers improve treatment of glioblastoma.

Zhou J, Patel TR, Sirianni RW, Strohbehn G, Zheng MQ, Duong N, Schafbauer T, Huttner AJ, Huang Y, Carson RE, Zhang Y, Sullivan DJ Jr, Piepmeier JM, Saltzman WM.

Proc Natl Acad Sci U S A. 2013 Jul 16;110(29):11751-6. doi: 10.1073/pnas.1304504110. Epub 2013 Jul 1.

5.

Genomic analysis of non-NF2 meningiomas reveals mutations in TRAF7, KLF4, AKT1, and SMO.

Clark VE, Erson-Omay EZ, Serin A, Yin J, Cotney J, Ozduman K, Avşar T, Li J, Murray PB, Henegariu O, Yilmaz S, Günel JM, Carrión-Grant G, Yilmaz B, Grady C, Tanrikulu B, Bakircioğlu M, Kaymakçalan H, Caglayan AO, Sencar L, Ceyhun E, Atik AF, Bayri Y, Bai H, Kolb LE, Hebert RM, Omay SB, Mishra-Gorur K, Choi M, Overton JD, Holland EC, Mane S, State MW, Bilgüvar K, Baehring JM, Gutin PH, Piepmeier JM, Vortmeyer A, Brennan CW, Pamir MN, Kiliç T, Lifton RP, Noonan JP, Yasuno K, Günel M.

Science. 2013 Mar 1;339(6123):1077-80. doi: 10.1126/science.1233009. Epub 2013 Jan 24.

6.

Low-grade gliomas: when and how to treat.

Omay SB, Piepmeier JM, Knisely JP.

Hematol Oncol Clin North Am. 2012 Aug;26(4):797-809. doi: 10.1016/j.hoc.2012.05.001. Epub 2012 Jun 7. Review.

PMID:
22794284
7.

Role of neurosurgery and radiation therapy in the management of brain tumors.

Patel TR, Yu JB, Piepmeier JM.

Hematol Oncol Clin North Am. 2012 Aug;26(4):757-77. doi: 10.1016/j.hoc.2012.04.001. Epub 2012 May 18. Review.

PMID:
22794282
8.

Neurosurgical approach.

Moliterno JA, Patel TR, Piepmeier JM.

Cancer J. 2012 Jan-Feb;18(1):20-5. doi: 10.1097/PPO.0b013e3183243f6e3. Review.

PMID:
22290253
9.

Polymeric nanoparticles for drug delivery to the central nervous system.

Patel T, Zhou J, Piepmeier JM, Saltzman WM.

Adv Drug Deliv Rev. 2012 May 15;64(7):701-5. doi: 10.1016/j.addr.2011.12.006. Epub 2011 Dec 20. Review.

10.

Biodegradable poly(amine-co-ester) terpolymers for targeted gene delivery.

Zhou J, Liu J, Cheng CJ, Patel TR, Weller CE, Piepmeier JM, Jiang Z, Saltzman WM.

Nat Mater. 2011 Dec 4;11(1):82-90. doi: 10.1038/nmat3187.

11.

Giant myofibroma of the orbit in an adult male.

Servat JJ, Williamson JE, Piepmeier J, Sinard J, Bernardino CR.

Orbit. 2012 Feb;31(1):21-3. doi: 10.3109/01676830.2011.605501. Epub 2011 Oct 18.

PMID:
22007896
12.

Convection-enhanced delivery of camptothecin-loaded polymer nanoparticles for treatment of intracranial tumors.

Sawyer AJ, Saucier-Sawyer JK, Booth CJ, Liu J, Patel T, Piepmeier JM, Saltzman WM.

Drug Deliv Transl Res. 2011 Feb 1;1(1):34-42. doi: 10.1007/s13346-010-0001-3.

13.

Phase III randomized trial of CED of IL13-PE38QQR vs Gliadel wafers for recurrent glioblastoma.

Kunwar S, Chang S, Westphal M, Vogelbaum M, Sampson J, Barnett G, Shaffrey M, Ram Z, Piepmeier J, Prados M, Croteau D, Pedain C, Leland P, Husain SR, Joshi BH, Puri RK; PRECISE Study Group.

Neuro Oncol. 2010 Aug;12(8):871-81. doi: 10.1093/neuonc/nop054. Epub 2010 Feb 4.

14.

Poor drug distribution as a possible explanation for the results of the PRECISE trial.

Sampson JH, Archer G, Pedain C, Wembacher-Schröder E, Westphal M, Kunwar S, Vogelbaum MA, Coan A, Herndon JE, Raghavan R, Brady ML, Reardon DA, Friedman AH, Friedman HS, Rodríguez-Ponce MI, Chang SM, Mittermeyer S, Croteau D, Puri RK; PRECISE Trial Investigators.

J Neurosurg. 2010 Aug;113(2):301-9. doi: 10.3171/2009.11.JNS091052.

PMID:
20020841
15.

The future of neuro-oncology.

Piepmeier JM.

Acta Neurochir (Wien). 2009 Nov;151(11):1343-8. doi: 10.1007/s00701-009-0471-6. Epub 2009 Jul 29. No abstract available.

PMID:
19639245
16.

Primary, non-exophytic, optic nerve germ cell tumors.

DiLuna ML, Two AM, Levy GH, Patel T, Huttner AJ, Duncan CC, Piepmeier JM.

J Neurooncol. 2009 Dec;95(3):437-443. doi: 10.1007/s11060-009-9941-1. Epub 2009 Jun 25.

PMID:
19554263
17.

Anaplastic oligoastrocytoma in Turcot syndrome.

Baehring J, Hui P, Piepmeier J, Bannykh SI.

J Neurooncol. 2009 Nov;95(2):293-298. doi: 10.1007/s11060-009-9928-y. Epub 2009 Jun 4.

PMID:
19495563
18.

Current concepts in the evaluation and management of WHO grade II gliomas.

Piepmeier JM.

J Neurooncol. 2009 May;92(3):253-9. doi: 10.1007/s11060-009-9870-z. Epub 2009 Apr 9. Review.

PMID:
19357953
19.

Neurosurgery. Prefaces.

Andrews DW, Yu C, Gutin PH, Piepmeier JM.

Neurosurgery. 2009 Feb;64(2 Suppl):A2-6. doi: 10.1227/01.NEU.0000312702.38535.D4. No abstract available.

PMID:
19165070
20.

Intracranial benign fibrous histiocytomas: a case report and review.

Moliterno JA, Sood S, Zambrano E, Kim JH, Piepmeier JM, Baehring JM.

J Neurooncol. 2009 Apr;92(2):203-9. doi: 10.1007/s11060-008-9743-x. Epub 2008 Nov 22. Review.

PMID:
19030779

Supplemental Content

Loading ...
Support Center